Better access to health care is key to higher survival rates for African-Americans with colon cancer

August 06, 2002

BOSTON ---- African-Americans with colon cancer are more likely to die from the disease than are whites, but a new study has found that those survival rate disparities virtually disappear when both groups have equal access to chemotherapy after surgery. Led by investigators at Dana-Farber Cancer Institute, the research team also discovered that African-Americans were less likely than whites to experience some chemotherapy side-effects, including diarrhea and nausea.

The study, published in the Aug. 7 issue of the Journal of the National Cancer Institute, provides new evidence that a lack of access to quality care, rather than an innate biological difference, is largely to blame for the generally lower survival rates of African-Americans with colon cancer, the authors say.

"Most researchers have suspected that the lower survival rate among African-Americans with colon cancer is due to variations in the availability of adequate medical care rather than any unique characteristics of their tumors," says the study's senior author, Charles Fuchs, M.D., of Dana-Farber. "This study indicates that when African-American and white patients receive the same basic treatment for the disease - surgery followed by chemotherapy - they fare equally well."

Data for the study came from a clinical trial designed to measure the effectiveness of chemotherapy for colon cancer patients who had undergone surgery to remove cancerous portions of their colons.

Fuchs and his colleagues compared survival rates and the level of side effects in 344 African-American and 3,036 white patients enrolled in the trial. The patients all had cancer of the colon that was removed surgically within the prior six weeks. As part of the trial, all patients received six to eight weeks of chemotherapy after surgery.

The investigators found no major differences in survival rates for the two groups five years after treatment. The African-American patients had a 65 percent overall survival rate compared to 66 percent for the white patients. Similarly, they had a 57 percent recurrence-free survival rate and the white patients had a 58 percent rate.

The data also showed that white patients were significantly more likely than African-American patients to experience chemotherapy-related side effects, including diarrhea (sometimes severe), nausea, vomiting, and stomatitis (an inflammation of the mouth). The reasons for these differences in chemotherapy-related side effects aren't clear, Fuchs and his co-authors write, but may have to do with undefined genetic differences between whites and African-Americans in the general population.

Although previous studies have found that African-Americans with colon cancer generally don't survive as long as whites with the disease, the new study is one of the first to compare survival rates when the availability of quality care is equal for all patients. If African-Americans as a group have poorer access to such care, their tumors are less likely to be detected and treated at an early stage, when prospects for recovery are best.

"Our study shows the value of the National Cancer Institute's efforts to increase African-Americans' participation in clinical trials," explains the study's first author, A. David McCollum, M.D., who conducted the research while he was at Dana-Farber and is now a practicing oncologist in Texas. "Increased enrollment by members of minority groups will ultimately lead to better care for people in traditionally underserved populations."
-end-
Contributing to the study were investigators at the University of Pennsylvania Cancer Center, St. Vincent Clinical Cancer Center in New York City, and Northwestern University.

The study was funded in part by grants from the National Cancer Institute and Dana-Farber.

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Dana-Farber Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.